SAVA

Take Full Advantage Of Weakness In Cassava Sciences Stock

by Ian Cooper
April 27, 2022April 17, 2023

Investors may want to keep an eye on oversold shares of Cassava Sciences (NASDAQ:SAVA). Even with the broader market down 500 points on the day,… Read More »Take Full Advantage Of Weakness In Cassava Sciences Stock

Does Cassava Sciences And Its Alzheimer’s Drug Really Have What It Takes?

by Dana Blankenhorn
February 11, 2022April 17, 2023

Cassava Sciences (NASDAQ:SAVA) stock illustrates the promise — and hazards — in biotechnology investing. Casssava management says it has a drug that can effectively treat… Read More »Does Cassava Sciences And Its Alzheimer’s Drug Really Have What It Takes?